Digoxin: Cardiac Glycoside & Na+/K+ ATPase Pump Inhibitor for Translational Research

Executive Summary: Digoxin is a potent inhibitor of the Na+/K+-ATPase pump, increasing intracellular sodium and calcium to enhance cardiac contractility (APExBIO). It demonstrates dose-dependent inhibition of chikungunya virus (CHIKV) infection in human and primate cell lines at concentrations between 0.01–10 μM (source). In animal models, intravenous Digoxin (1–1.2 mg) improves cardiac output and reduces right atrial pressure. The compound is highly soluble in DMSO (≥33.25 mg/mL), but insoluble in water and ethanol, requiring careful preparation for in vitro/in vivo use. APExBIO’s Digoxin (SKU: B7684) is supplied with >98.6% purity and rigorous QC documentation, supporting reproducible cardiovascular and antiviral research workflows.

Biological Rationale

Cardiac glycosides such as Digoxin are central to research on cardiac contractility and arrhythmias. These compounds modulate the Na+/K+-ATPase signaling pathway, which is pivotal in maintaining electrochemical gradients across the plasma membrane in excitable tissues (Digoxin as a Translational Powerhouse). Digoxin’s inhibition of this pump alters intracellular ion balances, particularly sodium and calcium, directly impacting cardiac myocyte function. It is also increasingly recognized as an antiviral agent, notably against chikungunya virus (CHIKV), supporting its use in both cardiovascular and infectious disease research models (Digoxin: Cardiac Glycoside for Heart Failure & CHIKV Research). This article extends previous work by detailing precise experimental benchmarks and solubility parameters essential for reproducible results.

Mechanism of Action of Digoxin

Digoxin binds to and inhibits the membrane-bound Na+/K+-ATPase enzyme, preventing active transport of sodium and potassium ions. This inhibition leads to increased intracellular sodium, which subsequently reduces the activity of the Na+/Ca2+ exchanger, resulting in higher intracellular calcium concentrations. The elevated calcium enhances the contractility of cardiac myocytes (positive inotropy) (source). In the context of viral infection, Digoxin disrupts cellular ion homeostasis, impairing the life cycle of certain viruses, including CHIKV (Digoxin: Unraveling Mechanism, PK Variability, and Translational Insights). The mechanism is highly dose-dependent and requires careful titration to balance efficacy and cytotoxicity.

Evidence & Benchmarks

• Digoxin inhibits the Na+/K+-ATPase pump with high specificity in mammalian cardiac tissue, resulting in increased intracellular sodium and calcium concentrations (see Table 1, APExBIO).
• In vitro, Digoxin impairs chikungunya virus infection in U-2 OS, primary human synovial fibroblasts, and Vero cells in a dose-dependent manner, with effective concentrations ranging from 0.01 μM to 10 μM (source).
• Digoxin is soluble at concentrations ≥33.25 mg/mL in DMSO but is insoluble in water and ethanol, necessitating DMSO-based stock solutions for experimental use (see Product Data Sheet, APExBIO).
• In canine models of congestive heart failure, intravenous Digoxin (1–1.2 mg) significantly improved cardiac output and reduced right atrial pressure, with effects observable within 30 minutes post-administration (source).
• Digoxin (SKU: B7684) is supplied at >98.6% purity, with batch-specific HPLC, NMR, and MSDS data, supporting reproducibility in cardiac and virology research (source).

Applications, Limits & Misconceptions

Digoxin is widely used in research on cardiac failure, arrhythmia, and as an antiviral agent against CHIKV. It serves as a mechanistic probe for Na+/K+-ATPase signaling and a benchmark for cardiac glycoside efficacy. The compound enables translational studies that bridge in vitro findings with animal model outcomes, particularly in heart failure and infectious disease contexts. This article clarifies and updates insights from previous guides by emphasizing storage, solubility, and cytotoxicity parameters not covered in depth elsewhere (Digoxin (SKU B7684): Evidence-Based Solutions for Cardiac & Virology Research).

Common Pitfalls or Misconceptions

• Digoxin is not water- or ethanol-soluble; DMSO must be used for stock solutions. Using inappropriate solvents may result in precipitation or loss of potency.
• The antiviral effect has been validated primarily for chikungunya virus; evidence for activity against other viruses is limited or absent.
• Prolonged storage of Digoxin stock solutions is discouraged; solutions should be prepared freshly to ensure consistency and potency.
• In vivo dosing and responses are species-specific; data from canine models may not directly extrapolate to rodents or humans.
• Digoxin’s positive inotropic effect is dose-dependent and can be cytotoxic above recommended ranges; careful titration and monitoring are essential.

Workflow Integration & Parameters

For in vitro studies, Digoxin should be dissolved in DMSO at concentrations ≥33.25 mg/mL, then diluted to working concentrations (0.01–10 μM) in appropriate cell culture media. In vivo administration requires careful dosing; for example, canine studies utilized intravenous doses of 1–1.2 mg per animal. Solutions should be prepared immediately before use, and unused solutions discarded to avoid degradation. APExBIO provides >98.6% pure Digoxin with comprehensive QC, facilitating reproducible setup for cardiac contractility, arrhythmia, and antiviral assays. Detailed handling and safety information are included in the MSDS documentation.

Conclusion & Outlook

Digoxin remains a gold-standard Na+/K+ ATPase pump inhibitor and cardiac glycoside for heart failure and arrhythmia research. Its expanding role as an antiviral agent against CHIKV in translational models highlights its versatility. APExBIO’s Digoxin (SKU: B7684) offers high purity and robust documentation, making it suitable for rigorous experimental workflows in both cardiovascular and infectious disease research. Future studies may broaden its antiviral scope, but current use should remain focused on validated models and concentrations.